ketanserin has been researched along with sorafenib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Chen, G; Huang, N; Huang, XP; Lin, X; Peng, S; Roth, BL; Wang, S; Wang, SX; Wang, Y; Whaley, R; Zhang, G | 1 |
2 other study(ies) available for ketanserin and sorafenib
Article | Year |
---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cyproheptadine; Drug Approval; Drug Discovery; Ketanserin; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Protein Conformation; Pyridines; Receptors, Serotonin; Sequence Homology, Amino Acid; Serotonin Antagonists; Sorafenib; United States; United States Food and Drug Administration; User-Computer Interface | 2012 |